Elevated levels of D-dimer have been found in the blood of patients with pulmonary embolism (PE) and deep vein thrombosis (DVT). The elevated level of D-dimer in blood is believed to be a reliable marker of pathological coagulation. During the COVID-19 pandemic D-dimer has been commonly elevated in patients with SARS-CoV-2. It has been shown to correlate with disease severity and to be a reliable prognostic marker for hospitalization and mortality assessment in patients admitted for COVID-19.

D-dimer (MW 180 kDa) is the final product of fibrin degradation. It consists of the remnants of all three chains (α, β and γ chains) of fibrinogen cross linked by disulfide bonds. The dimeric structure of D-dimer is held by two covalent, intermolecular isopeptide bonds between the γ-chains.

For development of D-dimer assays, we provide several monoclonal antibodies specific for D-dimer and FDP. The recommended capture-detection pairs for sandwich immunoassays are shown in Table 1.

TABLE 1. Recommended pairs to be used in a sandwich immunoassay for D-dimer detection in human plasma.

Learn more:
D-dimer TechNotes
Cat# 4D30: D-dimer human, antibody
Cat# 8D70: D-dimer, antigen